CONSOLIDATED STATEMENTS OF (LOSS) INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues
Product sales	$ 1,506,421	$ 852,747	$ 3,608,801	$ 2,346,599
Alliance and royalty	16,471	12,248	39,651	148,348
Service and other	18,839	19,145	57,396	65,386
Total revenues	1,541,731	884,140	3,705,848	2,560,333
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	560,855	216,494	1,128,942	633,618
Cost of alliance and service revenues	14,353	13,758	44,241	118,237
Selling, general and administrative	355,637	188,660	854,909	551,386
Research and development	49,009	19,170	97,273	58,887
Amortization and impairments of finite-lived intangible assets (see Note 10)	910,248	218,187	1,540,021	629,400
Restructuring, integration and other costs	295,890	42,872	398,540	135,213
In-process research and development impairments and other charges	123,981	145,300	128,811	149,868
Acquisition-related costs	8,650	4,605	24,428	25,977
Legal settlements and related fees	149,601	0	155,173	56,779
Acquisition-related contingent consideration	(34,995)	5,630	(33,511)	23,198
Total expenses	2,433,229	854,676	4,338,827	2,382,563
Operating (loss) income	(891,498)	29,464	(632,979)	177,770
Interest income	2,686	1,156	5,336	3,299
Interest expense	(249,306)	(116,042)	(581,414)	(318,681)
Loss on extinguishment of debt	(8,161)	(2,322)	(29,540)	(2,455)
Foreign exchange and other	5,079	(1,603)	(3,564)	18,458
Gain on investments, net	0	0	5,822	2,024
Loss before recovery of income taxes	(1,141,200)	(89,347)	(1,236,339)	(119,585)
Recovery of income taxes	(169,225)	(96,992)	(247,700)	(92,702)
Net (loss) income	(971,975)	7,645	(988,639)	(26,883)
Less: Net income attributable to noncontrolling interest	1,268	0	1,268	0
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (973,243)	$ 7,645	$ (989,907)	$ (26,883)
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (loss) earnings per share (dollars per share)	$ (2.92)	$ 0.03	$ (3.13)	$ (0.09)
Diluted (loss) earnings per share (dollars per share)	$ (2.92)	$ 0.02	$ (3.13)	$ (0.09)
Weighted-average common shares (000s)
Basic (in shares)	333,643	304,075	316,462	305,550
Diluted (in shares)	333,643	311,743	316,462	305,550